GENE: Rega marang dodolan GTG Labs

Genetic Technologies develops patent-protected AI algorithms for the early detection of oncology and cardiac pathologies. The price-to-sales ratio reflects the market valuation of revenue, with the value fixed at 0.70. Market capitalization is based on the preventive diagnosis of cancer and diabetes. The company is currently scaling its commercial operations through B2B partnerships with the insurance sector and the expansion of digital marketing.

The P/S ratio compares market capitalization to sales volume, allowing an investor to assess the extent of overpayment for an asset relative to its ability to generate revenue. When analyzing the current P/S level on the GURU.Markets platform, it should be noted that for Genetic Technologies (GENE), this metric reflects market expectations regarding the scaling of robotic DNA sequencing systems and the implementation of AI-driven oncology risk diagnostics.